Proteintech Germany triples its space with a new office and laboratory
20.3.2024 21:57:00 EET | Business Wire | Press release
Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320643097/en/
Proteintech celebrates the opening with a ribbon cutting event. Pictured: Dr. Jason Li, CEO of Proteintech, along with Proteintech executives and local government officials. (Photo: Business Wire)
In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-based reagents and was located at the incubator IZB. The gradual integration of Chromotek into the parent company, Proteintech Group, enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the European Union.
Rainer Gebhart, Site Manager at Proteintech Germany, said: “Here we offer state-of-the-art working environments for daily top performance and innovation of our employees - our most important capital for a continued successful future.” He also explained, “The move supports our customer focused strategy. With a larger team in Martinsried – and in cooperation with our sister site in Manchester, UK – we can better serve our customers in Europe and further gain market share.”
Dr Jason Li, CEO of Proteintech said, “There is a great future for Nanobody technology and we’re excited to be at the forefront of this.” He also stated, “Proteintech has R&D and production laboratories on three continents in its major sites (Chicago, Wuhan and Martinsried). All three sites have seen expansion in the past year and the collaboration between them means we can bring new and innovative products to the market.”
About Proteintech Group
Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 200,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.
To learn more about Proteintech, please visit www.ptglab.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320643097/en/
Contact information
Katie Bellows
katie@ptglab.com
ph. +1-312-455-8498
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Selected by Microsoft as Launch Partner for Agent 365, Supporting the Governance and Scaling of AI agents8.4.2026 11:17:00 EEST | Press release
Reply [EXM, STAR: REY] has been confirmed one of a small number of Launch Partners for Agent 365, supporting the general availability of Microsoft's new platform designed to provide enterprise-grade governance, observability and lifecycle management for AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408212380/en/ Through this collaboration with Microsoft, Reply reinforces its commitment to enabling organisations to implement artificial intelligence responsibly and at scale, supporting long-term digital transformation objectives. Microsoft Agent 365 introduces a structured framework enabling organisations to deploy, monitor and manage AI agents consistently across business functions. As artificial intelligence becomes embedded in core operational processes, Agent 365 provides clarity, control and accountability, ensuring that AI-driven activities remain transparent, secure and aligned with organisational objecti
HPE Takes Licence to Patents Offered Through the Sisvel Wi-Fi Multimode Pool8.4.2026 11:00:00 EEST | Press release
Hewlett Packard Enterprise (HPE) has become the latest company to take a licence to the patents offered through the recently launched Sisvel Wi-Fi Multimode pool. It joins Sony Group Corporation, Huawei, Panasonic, Philips and ZTE as a licensee of the programme. The latter four are also licensors, along with KPN, Mitsubishi Electric, Orange, Aegis 11 SA (a Sisvel affiliate), SK Telecom and Wilus. HPE is a major presence in the global WLAN market and is a leading manufacturer of both consumer and enterprise routers. The deal with Sisvel was reached on an amicable basis. The Sisvel Wi-Fi Multimode pool is the successor programme to the Sisvel Wi-Fi 6 patent pool. Over a three-year period, this closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP. Covering Wi-Fi 7 as well as 6, the Multimode programme offers an efficient way to access essential Wi-Fi rights for years to come. “We are delighted to welcome Hewlett Packard Enterprise as the latest licensee of the
Zyxel and Openreach Team Up to Reduce Plastic Waste in Full Fibre Installations8.4.2026 11:00:00 EEST | Press release
A new partnership between Zyxel Communications and Openreach is helping to cut plastic and packaging waste from the UK’s Full Fibre rollout - by deploying re-cycled ‘modems’ to connect customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408766604/en/ Openreach - GPON ONT Zyxel is deploying a range of new Optical Network Terminals (ONTs) - the wall-mounted box of electronics that converts optical signals into electrical ones used by household devices - with re-engineered casings made from 95 per cent recycled plastic.1 Openreach engineers have already installed half a million of Zyxel’s sustainable ONTs and the network provider expects to install even more this year as customers upgrade to Full Fibre - the UK’s most reliable broadband technology. The GPON2 devices use recycled plastic in their construction and arrive in zero‑plastic minimal packaging made from recycled materials. Openreach is working with Zyxel and o
Jeito Capital Hits Record $1.2 Billion (€1 Billion) 1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 09:15:00 EEST | Press release
Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2billion (above €1billion)1,2, and marking a new major milestone for European Biopharma investment. With this new fund, Jeito has now tripled its assets under management to €1.6 billion, following the closing in 2021 of fund Jeito I at $630 million (€534 million) and reinforces its position as a leading fully independent European Biopharma investor. Jeito II will continue the strategy established with Jeito I: selectively identifying and backing 15 to 20 of the most promising clinical stage Biopharma companies, primarily in Europe, developing breakthrough therapies for severe diseases with high unmet medical needs and accelerating the development path and future market access. This fundraising allows Jeito to increase the average size of future investments in portfolio companies up to €150 million, thus drivi
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 08:00:00 EEST | Press release
Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of Synocrom™ also builds on Croma-Pharma’s long-standing expertise in the development and manufacturi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom